Indian pharmaceutical company Cipla is reportedly preparing for a significant management change. Umang Vohra, the company’s managing director and global CEO, is expected to step down by the end of the current fiscal year. Vohra, 54, has been in the role for nearly a decade. Achin Gupta, currently Cipla’s global chief operating officer, is likely to take over as his replacement. According to an industry executive, Gupta has been groomed for the role over the past few years and is expected to assume the position by March 2026.
Cipla is a major player in the pharmaceutical industry, manufacturing active pharmaceutical ingredients for other companies, as well as a range of pharmaceutical and personal care products. The company is the world’s largest producer of antiretroviral drugs and has a significant presence in over 80 countries worldwide. In India, Cipla operates 34 manufacturing units across eight locations.
One of Cipla’s notable achievements was the launch of Remdesivir, an antiviral medication, under the brand name CIPREMI in July 2020. The medication was approved for “restricted emergency use” in critically ill COVID-19 patients, following a voluntary licensing agreement with Gilead Sciences and approval from the Drug Controller General of India (DCGI).
The management change is expected to take place over the next year, with Gupta likely to take over the role of managing director and global CEO. The transition is seen as a planned move, with Gupta having been prepared for the position over the past few years. The change is expected to have a significant impact on the company’s operations and strategy, although the exact details of the transition are not yet clear.
Cipla’s products include a range of medications, such as escitalopram oxalate, lamivudine, and fluticasone propionate. The company’s global presence and reputation as a major pharmaceutical manufacturer make it a significant player in the industry. As the company prepares for the management change, it will be interesting to see how the transition affects its operations and strategy in the coming months.